ArticlePharmaceuticals (Basel, Switzerland)2026

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment.

Marko Lucijanic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.